Abstract
Until recently, the notion of having blood markers of Alzheimer disease (AD) available for clinical use was more likely to be seen in an episode of a TV medical drama or a science fiction movie than in a peer-reviewed scientific journal. The search for biomarkers suffered from serious obstacles, including, but not limited to, inadequate diagnostic accuracy, and an inability to replicate findings across samples between laboratories or even within individual laboratories. However, the serious scientific world took notice when, in 2007, Ray et al.1 published a plasma-based screening tool that utilized advanced proteomic and bioinformatics methods to create a blood profile that was highly accurate in identifying persons with AD as well as those who were most likely to progress from mild cognitive impairment (MCI) to AD dementia. Enthusiasm diminished, …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
